The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Injectable SPN01 in Phase I.

After each subject was randomly assigned, different doses of SPN01 for Injection (0.02 mg/kg, 0.06 mg/kg, 0.12 mg/kg) were administered intravenously in a single dose.

After each subject was randomly assigned, a single intravenous injection of 0.9% sodium chloride was administered

Colorectal cancer subjects will receive intravenous injection of SPN01 0.06 mg/kg for a single dose.